Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OMGA | US
0.14
14.96%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.04
0.89
1.06
0.89
Omega Therapeutics Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases such as neutrophilic asthma acute respiratory distress syndrome dermatological oncology and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition the company develops OEC candidates for the treatment of alopecia a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics Inc. was incorporated in 2016 and is headquartered in Cambridge Massachusetts.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
99.8%1 month
83.2%3 months
69.9%6 months
88.8%-
-
2.02
4.83
0.75
-2.12
21.23
-
-78.89M
59.05M
59.05M
-
-776.95
-
181.20
-129.15
38.92
29.28
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.27
Range1M
0.64
Range3M
1.25
Rel. volume
2.63
Price X volume
568.63K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 2.09 | 62.68M | -5.86% | n/a | 6.50% |
iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 4.44 | 60.36M | -2.63% | n/a | -2140.66% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.816 | 59.54M | -8.80% | n/a | 11.69% |
RAPT THERAPEUTICS INC. | RAPT | Biotechnology | 1.69 | 58.99M | -3.43% | n/a | 5.24% |
CEL-SCI Corporation | CVM | Biotechnology | 0.95 | 58.42M | -3.57% | n/a | 143.19% |
Allakos Inc | ALLK | Biotechnology | 0.65 | 57.75M | -1.28% | n/a | 47.30% |
CELU | CELU | Biotechnology | 2.6 | 57.16M | -6.47% | n/a | 159.71% |
Kronos Bio Inc | KRON | Biotechnology | 0.93 | 56.07M | -3.63% | n/a | 22.03% |
Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.72 | 53.59M | 2.38% | n/a | 4.22% |
OncoCyte Corporation | OCX | Biotechnology | 3.12 | 53.39M | 0.32% | n/a | 16.15% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.12 | 0.53 | Cheaper |
Ent. to Revenue | 21.23 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 2.02 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 69.87 | 72.92 | Par |
Debt to Equity | 4.83 | -1.24 | Expensive |
Debt to Assets | 0.75 | 0.25 | Expensive |
Market Cap | 59.05M | 3.78B | Emerging |